Market Research Logo

Major World Markets for Stents and The Economics of Drug-Eluting Technology

Since the arrival of drug-eluting (called drug-eluding by some) technology a few years ago with the promise of reducing restenosis, questions abound surrounding the future of the stent market: After numerous clinical studies and mixed cost-effectiveness results, how is drug-eluding technology expected to peform in the future? What can companies do to best market this technology in the healthcare system of the US and 6 other major world markets? What are the market trends to watch that will determine growth in this field in the coming years? What companies have already established a leadership position in stents and what do start ups have to do to join them? Major World Markets for Stents and The Economics of Drug Eluding Technology, written by Kalorama Analyst Dr. Kenneth Krul, takes a hard look at these questions with economic analysis unmatched by any resource.

The field of drug-eluting stents remains an exciting technological innovation that will be a major part of cardiovascular intervention technologies over the next ten years. This report provides a complete market assessment for coronary stents broadly, with emphasis on the economics of drug-eluting stents. Markets sizes and forecasts are divided in two product segments:

  • Bare Metal (BMS)
  • Drug Eluding Stents (DES)

As a world market analysis, the report covers markets in the following countries:

  • U.S.
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Japan

This report considers the options that the current technologies present, the progress that is being made in these fields, and the reception these new products are likely to experience in the marketplace. In its brief lifetime (BMSs having only emerged fully in the mid-1990s), the field of coronary stents has shown that it can hold many surprises. Among the information in this complete survey of the coronary stent market, the report contains:

  • Discussion of Restenosis and its Implications
  • Major World Market Size for BMS and DES
  • Statistics Driving Stent Usage
  • Forecasts in Major World Markets to 2012
  • The Economic Case for Drug-Eluting Stent Technologies and Applications
  • Successful Marketing Strategies
  • Profiles of Key Stent Companies
  • Most Favorable Markets for Stent Manufacturers
  • Nine Strategic Conclusions Essential to The Market

The analysis presented in this report is based on data from a combination of company, government, industrial, institutional and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including experts in cardiology and cardiac surgery, as well as pathologists, public health experts, research scientists, and business development and marketing managers engaged in the field.


  • Executive Summary
    • BACKGROUND
      • Table Projected Deaths from Ischemic Heart Disease (IHD) and Acute Myocardial Infarction (AMI) in the Seven Major World Healthcare Markets: 2008
    • SCOPE AND METHODOLOGY
    • SIZE AND GROWTH OF MARKET
      • Table The Estimated Total Market for Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and 2018
      • Table The Estimated Market for Bare Metal Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and 2018 (in $ millions)
      • Table The Estimated Market for Drug-Eluting Coronary Stents in the Seven Major World Healthcare Markets: 2008, 2013 and 2018 (in $ millions)
  • Overview: Cardiovascular Disease and Coronary Stents
    • BACKGROUND
      • Table Top Ten Major Causes of Death in the World By Region
      • Table Top Ten Major Causes of Death in the World By Regional Development Level: (Developing Countries, Developed Countries) 2001
      • Table Top Ten Major Causes of Death in the World By Income Level: 2001
      • Table Projected Deaths from Ischemic Heart Disease (IHD) and Acute Myocardial Infarction (AMI) in the Seven Major World Healthcare Markets: 2008
      • Table Distribution of Projected Ischemic Heart Disease Fatalities in the Seven Major World Healthcare Markets: 2008
      • Table Distribution of Projected Acute Myocardial Infarction Fatalities in the Seven Major World Healthcare Markets: 2008
    • STENTS,COATINGS AND SUBACUTE THROMBOSIS
    • DRUG ELUTING STENT TECHNOLOGY
      • Problems
    • ALTERNATIVES TO DRUG -ELUTING STENTS
      • Branchytherapy
      • Biochemical Approaches
      • Pharmaceutical Approaches
  • The Economics Of Coronary Stents
    • Direct and Indirect Costs of Stents
      • Table Economic Burden (Direct Costs) of Restenosis*
      • ACC Study
      • Factors behind Drug Eluding Stent Adoption
        • Table Medicare Trends in Coronary Revascularization Therapy: 1998 - 2001
      • Price of Stents
      • Restenosis and Mortality
        • Table Cost Per Repeated Revascularization Avoided
        • Table Willingness to Pay for Restenosis Prevention Technology
        • Table Predicted Clinical Restenosis Rates Following PTCA and Stent
        • Table Expected Cost-Effectiveness of Drug-Eluting Stents
  • Market Summary
    • Table IHD/CHD Heart Disease Age-Standardized Mortality Rates* for Both Sexes
    • Table Projected IHD/CHD Cases: 2008
    • DEMOGRAPHICS
      • Population
        • Table Projected Populations of the Seven Major World Markets: 2008 - 2018 (Millions)
      • Age
        • Table Ranking of the Major Causes of Death by Age Group in the United States: 2003
        • Table Trends in the Older (60+) Populations of the Seen Major World Healthcare Markets: 1950 - 2050 (Millions)
        • Table Increases in IHD/CHD Incidence* with Age
        • Table Crude Death Rates* Associated with CVD: 2004
        • Table Crude Death Rates* Associated with IHD/CHD: 2006
      • Sex
        • Table Expected Death Rates* from IHD/CHD and AMI for Men and Women in the Seven Major World Healthcare Markets: 2008
      • Race and Ethnicity
        • Table Death Rates* for CVD for Men by Race and Ethnicity in the United States: 1985 - 2002
        • Table Death Rates* for CVD for Women by Race and Ethnicity in the United States: 1985 - 2002
        • Table Major Causes of Death for White, Black, American Indian and Hispanic Males in the United States: 2004 (% of Deaths)
        • Table Major Causes of Death for White, Black, American Indian and Hispanic Females in the United States: 2004 (% of Deaths)
        • Table Deaths from CVD for White and Black Men in the United States by Age Group: 2004
        • Table Deaths from CVD for White and Black Women in the United States by Age Group: 2004
    • PUBLIC HEALTH ISSUES
      • Obesity
        • Table Percentage of Obesity in the Seven Major World Healthcare Markets: 2005
        • Table Prevalence of Obesity in the Seven Major World Healthcare Markets: 2004
        • Table Age-Adjusted Prevalence of Obesity* in Adult Americans (Ages 20 to 74) by Sex: 1960 - 2004
      • Smoking
        • Table Smoking Prevalence in the Seven Major World Healthcare Markets (Standardized Data - % of Population)
      • Hypertension
        • Table Prevalence of Hypertension in Americans Age 20 Years and Older by Age and Sex
      • Economics
        • Table Cost Estimates of Revascularization Using Drug-Eluting Stents versus Bare Metal Stents: 2003
      • Political Factors
      • Market Estimates
        • Table The Estimated Total Market for Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018 (Millions)
        • Table The Estimated Market for Bare Metal Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018 (Millions)
        • Table The Estimated Market for Drug-Eluting Coronary Stents in the Seven Major World Healthcare Markets: 2008 - 2018 (Millions)
      • The Upstarts
  • Company Summaries
    • OVERVIEW
    • ABBOTT VASCULAR (DIVISION OF ABBOTT LABORATORIES)
      • Table ABBOTT VASCULAR (DIVISION OF ABBOTT LABORATORIES)
    • ATRIUM MEDICAL CORPORATION
    • BOSTON SCIENTIFIC
      • Table BOSTON SCIENTIFIC
    • CELONOVA BIOSCIENCES
    • CONOR MEDSYSTEMS (AJOHNSON &JOHNSON COMPANY)
    • CORDIS CORPORATION (AJOHNSON &JOHNSON COMPANY)
    • MEDINOL LTD.
    • MEDTRONIC,INC.
      • Table MEDTRONIC,INC.
    • MIV THERAPEUTICS,INC.
    • ORBUSNEICH
    • STENTYS S.A.S.
    • TERUMO MEDICAL CORPORATION
    • XTENT, INC.
  • Conclusions and Strategic Implications
    • FIRST CONCLUSION
      • Implications:
    • SECOND CONCLUSION
      • Implications:
    • THIRD CONCLUSION
      • Implications:
    • FOURTH CONCLUSION
      • Implications:
    • FIFTH CONCLUSION
      • Implications:
    • SIXTH CONCLUSION
      • Implications:
    • SEVENTH CONCLUSION
      • Implications:
    • EIGHTH CONCLUSION
      • Implications:
    • NINTH CONCLUSION
      • Implications:

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report